A diverse, resilient supply chain for prescription medicine will moderate the risk of drug shortages and ensure patient access during the COVID-19 pandemic and beyond.
- Developers of generic and biosimilar medicines support diversification of the pharmaceutical supply chain — and incentives to increase manufacturing in the United States — but we must not hinder our response to the COVID-19 emergency.
- Any draconian restrictions on sourcing of ingredients or finished products could limit the ability of the U.S. government to provide medicines to veterans, soldiers and other patients during or after this time of national emergency.
Issues